ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES -
Life sciences companies are forming AI-driven strategic collaborations with tech giants, creating synergy that promises to revolutionize the industry. Companies like NVIDIA,...more
8/20/2024
/ Algorithms ,
America Invents Act ,
Artificial Intelligence ,
Bayh-Dole Act ,
Chevron Deference ,
Healthcare ,
Inflation Reduction Act (IRA) ,
Innovative Technology ,
Intellectual Property Protection ,
Life Sciences ,
Machine Learning ,
March-in-Rights ,
NIST ,
Non-Compete Agreements ,
Patents ,
Post-Grant Review ,
Prior Art ,
USPTO
Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground for the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) from January 7-10. While still less crowded than...more
1/22/2024
/ Acquisitions ,
Antitrust Provisions ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Health Care Providers ,
Healthcare ,
Healthcare Reform ,
Initial Public Offering (IPO) ,
Life Sciences ,
Medicare ,
Mergers ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Private Equity
The Inflation Reduction Act (IRA), signed into law in August 2022, impacted a wide range of tax laws and touched many aspects of government. Significantly, part of the IRA provides Medicare with the ability to negotiate the...more
7/21/2023
/ Artificial Intelligence ,
Benchmarking ,
Coronavirus/COVID-19 ,
Data Privacy ,
Data Protection ,
Department of Justice (DOJ) ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Inflation Reduction Act (IRA) ,
Intellectual Property Protection ,
Life Sciences ,
Non-Compete Agreements ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry
In today’s episode, leaders of Ballard’s Life Sciences Industry and Education Industry Teams consider the ongoing trends that they are seeing in both the education industry and the life sciences industry. We discuss sponsored...more
Summary -
In Amgen v. Sanofi, the Supreme Court unanimously affirmed the District of Delaware and Federal Circuit findings that Amgen’s functionally defined patent claims to a class of therapeutic antibodies are invalid as...more
Summary -
The 41st Annual JP Morgan Healthcare Conference in rainy San Francisco earlier this month was relatively low-key compared to pre-pandemic versions of the health care investment symposium, which returned this year...more
This episode is the first of a new podcast series, where we will visit with different leaders striving to grow economic development in their areas or regions of interest. We will be discussing new initiatives, new models, the...more
On May 8, 2020, the United States Patent and Trademark Office (US PTO) announced a new COVID-19 Prioritized Examination Pilot Program. The new pilot program provides an expedited prosecution of COVID-19-related patent...more
The U.S. Patent and Trademark Office (USPTO) last week established an updated patent fee schedule, effective January 16, 2018. The updated schedule provides for a modest increase for most fees—but also more significant...more
11/22/2017
/ Covered Business Method Patents ,
Design Patent ,
Fees ,
Filing Fees ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Applications ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
USPTO ,
Utility Patents
The U.S. Patent and Trademark Office (USPTO) has unveiled a series of new rules that provide for significant changes to the procedures followed in Patent Trial and Appeal Board (PTAB) proceedings, including inter partes...more
4/4/2016
/ Corporate Counsel ,
Covered Business Method Proceedings ,
Derivation Proceeding ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
USPTO ,
Young Lawyers
The Patent Trial and Appeal Board (Board) recently provided important guidance for prior art “printed publications” asserted in invalidity challenges under the 2011 Leahy-Smith America Invents Act (AIA) concerning a doctoral...more
For the first time, the U.S. Court of Appeals for the Federal Circuit recently ruled on a final decision of the Patent Trial and Appeal Board (PTAB) in an inter partes review proceeding, or IPR. In a 2-1 decision, the Federal...more
2/6/2015
Recently, the Federal Circuit had the opportunity to issue its first decision relating to biosimilars patent litigation and the Biologics Price Competition and Innovation Act of 2009 (BPCIA) procedures. Instead, the court...more
Over the last several months, universities and technology transfer programs have increasingly become the target of petitions for Inter Partes Review (IPR) filings. Effective September 16, 2012, IPR proceedings allow parties...more
Today the U.S. Supreme Court answered the question "Are human genes patentable?" The Court, in Association of Molecular Pathology et al. v. Myriad Genetics, Inc. et al., ruled that isolated DNA is a product of nature and not...more